Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estradiol valerate/dienogest - Bayer Schering Pharma

Next Previous
Drug Profile

Estradiol valerate/dienogest - Bayer Schering Pharma

Alternative Names: BAY 865027; Dienogest/estradiol valerate - Bayer Schering Pharma; DUB Qlaira; DUB-OC; E2/DNG - Bayer Schering Pharma; Natazia; Qlaira; SH T00658; SH T00658ID; SH T00658K; SH T00658L

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Oral contraceptives; Small molecules; Steroids; Testosterone congeners
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Metrorrhagia; Pregnancy

Most Recent Events

  • 16 Apr 2021 Discontinued - Phase-III for Metrorrhagia in China, Thailand, Taiwan (PO)
  • 01 Jun 2015 Bayer completes a phase III trial in Metrorrhagia in China, Philippines, Russia, Singapore, Taiwan and Thailand (NCT01638923)
  • 02 Mar 2015 Estradiol valerate/dienogest is still in a phase III trial for Metrorrhagia in China, Philippines, Russia, Singapore, Taiwan and Thailand (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top